Inhibitory effect of infliximab on orthodontic tooth movement in male rats.
Infliximab
Orthodontic tooth movement
Osteoclast
Tumour necrosis factor-α
Journal
Archives of oral biology
ISSN: 1879-1506
Titre abrégé: Arch Oral Biol
Pays: England
ID NLM: 0116711
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
received:
16
03
2022
revised:
09
10
2022
accepted:
16
10
2022
entrez:
7
11
2022
pubmed:
8
11
2022
medline:
9
11
2022
Statut:
ppublish
Résumé
This study aimed to investigate the effect of infliximab on orthodontic tooth movement in rats. Sixty male Sprague-Dawley rats were randomly divided into two groups: saline group and infliximab group. The two groups of rats received weekly intraperitoneally injection of saline or infliximab (5 mg/kg), respectively. After four weeks of injection, five rats in each group were euthanized and orthodontic appliances were placed in the other twenty-five rats each. On days 1, 3, 7, 14 and 21, five rats from each group were euthanised. Maxillae of all the rats were collected and examined by micro-computed tomography, haematoxylin and eosin staining, tartrate-resistant acid phosphatase staining, and immunohistochemical staining of tumour necrosis factor (TNF)-α, receptor activator of nuclear factor κB ligand (RANKL), receptor activator of nuclear factor κB (RANK), and osteoprotegerin (OPG). All data were analysed with Mann-Whitney test. Infliximab inhibited orthodontic tooth movement and decreased osteoclastogenesis on the compression side during orthodontic tooth movement. The elevated TNF-α level, induced by orthodontic force, was decreased by infliximab. Furthermore, infliximab reduced the expression of RANKL and RANK, while increased the expression of OPG on the compression side. Infliximab inhibits orthodontic tooth movement by reducing levels of TNF-α, RANKL, and RANK, while increasing level of OPG, and decreasing osteoclastogenesis on the compression side of periodontium.
Identifiants
pubmed: 36341994
pii: S0003-9969(22)00230-8
doi: 10.1016/j.archoralbio.2022.105573
pii:
doi:
Substances chimiques
Infliximab
B72HH48FLU
Tumor Necrosis Factor-alpha
0
RANK Ligand
0
Osteoprotegerin
0
Receptor Activator of Nuclear Factor-kappa B
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
105573Informations de copyright
Copyright © 2022 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Declarations of interest None.